Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
Maher K. Gandhi(Translational Research Institute), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Devinder Gill(Princess Alexandra Hospital), Jaikumar Duraiswamy(The University of Melbourne), Ujjwal Dua(The University of Melbourne), Paula Marlton(The University of Queensland), Eleanore Lambley(The University of Melbourne), Suzanne Elliott(The University of Melbourne), John F. Seymour(The Royal Melbourne Hospital), Corey Smith(QIMR Berghofer Medical Research Institute)
Cited by 250
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k